AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30866926 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma
Number of subjects: 922
Study 26864888 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologically informed practice (PIP) intervention for 12 months
Number of subjects: 0
Study 26864888 — intervention group
Group type: COMPARATOR
Intervention: Comparison group without PIP intervention
Number of subjects: 0
Study 25374138 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (20 μg/kg)
Number of subjects: 82
Study 25374138 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (0.5 mg/kg)
Number of subjects: 82
Study 25374138 — intervention group
Group type: COMPARATOR
Intervention: Control (5 ml saline)
Number of subjects: 82
Study 24620386 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing injection (100 mL added to 0.9% saline for 3 days preoperatively)
Number of subjects: 60
Study 24620386 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Xuebijing injection)
Number of subjects: 60
Study 21933609 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (10 mg per day for at least 3 days before procedure)
Number of subjects: 114
Study 21933609 — intervention group
Group type: COMPARATOR
Intervention: Control group (no benazepril)
Number of subjects: 114
Study 21933609 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril group
Number of subjects: 114
Study 21933609 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study 19330581 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy (IRT)
Number of subjects: 20
Study 19330581 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list (Control)
Number of subjects: 20
Study 16813587 — intervention group
Group type: COMPARATOR
Intervention: Short-course radiotherapy
Number of subjects: 0
Study 16813587 — intervention group
Group type: COMPARATOR
Intervention: Chemo-radiotherapy (CRT)
Number of subjects: 0
Study 16813587 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with oxaliplatin and irinotecan
Number of subjects: 0
Study 16813587 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted agents bevacizumab and cetuximab
Number of subjects: 0
Study 16813587 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant chemotherapy prior to preoperative CRT
Number of subjects: 0
Study 14970007 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemic clamps in Controls
Number of subjects: 19
Study 14970007 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemic clamps in ADX
Number of subjects: 19
Study 11437096 — intervention group
Group type: EXPERIMENTAL
Intervention: 148 MBq 89Sr i.v. (Group A)
Number of subjects: 50
Study 11437096 — intervention group
Group type: EXPERIMENTAL
Intervention: 1406 MBq 186Re‐HEDP i.v. (Group B)
Number of subjects: 50
Study 9250454 — intervention group
Group type: EXPERIMENTAL
Intervention: Lys(B28), Pro(B29) human insulin analog (insulin lispro)
Number of subjects: 12
Study 9250454 — intervention group
Group type: COMPARATOR
Intervention: Human regular insulin
Number of subjects: 12
Study 8252676 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 J biphasic shocks at axillary location
Number of subjects: 14
Study 8252676 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 J biphasic shocks at thoracic electrode locations
Number of subjects: 14
Study 8252676 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean single-shock DFT
Number of subjects: 14
Study 8252676 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 J shocks at axillary location
Number of subjects: 14
Study 8252676 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 J shocks at axillary location
Number of subjects: 14
Study 8252676 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy endocardial defibrillation at 10 J
Number of subjects: 14
Study 8252676 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 J shocks
Number of subjects: 14
Study 3613693 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 25 mg
Number of subjects: 10
Study 3613693 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 50 mg
Number of subjects: 10
Study 3613693 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 100 mg
Number of subjects: 10
Study 3613693 — intervention group
Group type: COMPARATOR
Intervention: Sulpiride 200 mg
Number of subjects: 10
Study 30761535 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality Salience (MS) condition
Number of subjects: 450
Study 30761535 — intervention group
Group type: COMPARATOR
Intervention: Frightening condition
Number of subjects: 450
Study 30761535 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 450
Study 30628540 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous saline bladder irrigation (CSBI)
Number of subjects: 151
Study 30628540 — intervention group
Group type: COMPARATOR
Intervention: Single immediate instillation of mitomycin C (SI-MMC)
Number of subjects: 151
Study 28639862 — intervention group
Group type: EXPERIMENTAL
Intervention: Weightlifting training session at 08:00
Number of subjects: 9
Study 28639862 — intervention group
Group type: EXPERIMENTAL
Intervention: Weightlifting training session at 14:00
Number of subjects: 9
Study 28639862 — intervention group
Group type: EXPERIMENTAL
Intervention: Weightlifting training session at 18:00
Number of subjects: 9
Study 26057685 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Youth Fit 4 Life protocol
Number of subjects: 0
Study 26057685 — intervention group
Group type: COMPARATOR
Intervention: Original Youth Fit For Life treatment
Number of subjects: 0
Study 23022645 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endoscopic surgery (<1 week after diagnosis)
Number of subjects: 100
Study 23022645 — intervention group
Group type: COMPARATOR
Intervention: Delayed endoscopic surgery (>6 months after diagnosis)
Number of subjects: 100
Study 20683051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential administration of cisplatin-etoposide followed by topotecan (arm A)
Number of subjects: 364
Study 20683051 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate administration of cisplatin-etoposide and topotecan (arm B)
Number of subjects: 364
Study 18434531 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-serotonin condition
Number of subjects: 0
Study 18434531 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 18434531 — intervention group
Group type: EXPERIMENTAL
Intervention: High-serotonin condition
Number of subjects: 0
Study 16880023 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak sense of coherence (SOC)
Number of subjects: 5866
Study 16880023 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak sense of coherence (SOC) in men aged >=55 years
Number of subjects: 5866
Study 16880023 — intervention group
Group type: COMPARATOR
Intervention: Strong sense of coherence (SOC)
Number of subjects: 5866
Study 14522530 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD) with oral and enteral polymyxin E, tobramycin, and amphotericin B combined with an initial 4-day course of intravenous cefotaxime
Number of subjects: 934
Study 14522530 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 934
Study 14522530 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 934
Study 11004613 — intervention group
Group type: COMPARATOR
Intervention: OKTcdr4a 225 mg/course (low dose)
Number of subjects: 28
Study 11004613 — intervention group
Group type: COMPARATOR
Intervention: OKTcdr4a 750 mg/course (high dose)
Number of subjects: 28
Study 11004613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11004613 — intervention group
Group type: EXPERIMENTAL
Intervention: OKTcdr4a 750 mg/course (high dose) after initial treatment
Number of subjects: 28
Study 11004613 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo or low-dose OKTcdr4a followed by high-dose OKTcdr4a
Number of subjects: 28
Study 9122545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact milk (240 or 360 mL)
Number of subjects: 960
Study 9122545 — intervention group
Group type: COMPARATOR
Intervention: Hydrolyzed milk (240 or 360 mL)
Number of subjects: 960
Study 9122545 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose intolerance
Number of subjects: 960
Study 1296499 — intervention group
Group type: EXPERIMENTAL
Intervention: ioversol 300 mg/ml
Number of subjects: 80
Study 1296499 — intervention group
Group type: COMPARATOR
Intervention: iohexol 300 mg/ml
Number of subjects: 80
Study 6691015 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly pelvic examinations starting at 37 weeks' gestation
Number of subjects: 349
Study 6691015 — intervention group
Group type: COMPARATOR
Intervention: No pelvic examinations until term or past term
Number of subjects: 349
Study 30639003 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate milk replacer (MOD)
Number of subjects: 48
Study 30639003 — intervention group
Group type: EXPERIMENTAL
Intervention: High milk replacer (HI)
Number of subjects: 48
Study 30639003 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin-oxytetracycline inclusion (NTMOD)
Number of subjects: 48
Study 29732651 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weekly 2‐hr workshop sessions
Number of subjects: 144
Study 29732651 — intervention group
Group type: EXPERIMENTAL
Intervention: web‐based modules
Number of subjects: 144
Study 29732651 — intervention group
Group type: COMPARATOR
Intervention: nonrandomised control group
Number of subjects: 144
Study 26628615 — intervention group
Group type: EXPERIMENTAL
Intervention: External stenting
Number of subjects: 24
Study 26628615 — intervention group
Group type: COMPARATOR
Intervention: No external stenting (unstented)
Number of subjects: 24
Study 24594499 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 25 mg intravenously
Number of subjects: 184
Study 24594499 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 2 mg intravenously
Number of subjects: 184
Study 23149532 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (150,000 IU vitamin D(3) orally)
Number of subjects: 84
Study 23149532 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (150,000 IU vitamin D(3) orally) over 12 weeks
Number of subjects: 84
Study 20159180 — intervention group
Group type: EXPERIMENTAL
Intervention: ACIDFORM gel (plus diaphragm)
Number of subjects: 120
Study 20159180 — intervention group
Group type: COMPARATOR
Intervention: K-Y Jelly (plus diaphragm)
Number of subjects: 120
Study 17664498 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention Care Management (PCM)
Number of subjects: 1316
Study 17664498 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (modified mammography telephone outreach program)
Number of subjects: 1316
Study 16109660 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI examination technique
Number of subjects: 36
Study 16109660 — intervention group
Group type: COMPARATOR
Intervention: Conventional enteroclysis
Number of subjects: 36
Study 11881521 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate 1332 to 1998 mg/day
Number of subjects: 753
Study 11881521 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate with psychosocial support (individual psychotherapy, group psychotherapy, behavioural therapy, brief intervention, family therapy)
Number of subjects: 753
Study 11881521 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 753
Study 11271401 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg) prior to encoding
Number of subjects: 48
Study 11271401 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg) at retrieval
Number of subjects: 48
Study 11271401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 11271401 — intervention group
Group type: EXPERIMENTAL
Intervention: Different drug state (DS) conditions
Number of subjects: 48
Study 11271401 — intervention group
Group type: EXPERIMENTAL
Intervention: Same drug state (SS)
Number of subjects: 48
Study 11271401 — intervention group
Group type: EXPERIMENTAL
Intervention: Different drug state (DS)
Number of subjects: 48
Study 9298634 — intervention group
Group type: EXPERIMENTAL
Intervention: Propentofylline (300 mg, three times daily 1 hour before meals)
Number of subjects: 260
Study 9298634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 8443935 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin emollient cream 0.01%
Number of subjects: 40
Study 3816685 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 0
Study 3816685 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0
Study 3816685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31758177 — intervention group
Group type: EXPERIMENTAL
Intervention: LID/ΔM2‐2/1030s vaccine (105 PFU, intranasal)
Number of subjects: 32
Study 31758177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 29518747 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose n-3 PUFA treatment (2 g/d)
Number of subjects: 74
Study 29518747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 27736365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad-viewing condition
Number of subjects: 3258
Study 27736365 — intervention group
Group type: COMPARATOR
Intervention: No-exposure control condition
Number of subjects: 3258
Study 25277887 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 82
Study 25277887 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 23598534 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam HCl (C-HCl)
Number of subjects: 21
Study 20950329 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 541
Study 20950329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 541
Study 18258627 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (100, 200, or 300 microg Se/d as high-selenium yeast)
Number of subjects: 501
Study 18258627 — intervention group
Group type: COMPARATOR
Intervention: Placebo yeast
Number of subjects: 501
Study 16771810 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA/Aza
Number of subjects: 84
Study 16771810 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA/MMF
Number of subjects: 84
Study 16771810 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacr/Aza
Number of subjects: 84
Study 16771810 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV disease
Number of subjects: 84
Study 12748513 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical artery Doppler testing
Number of subjects: 1360
Study 12748513 — intervention group
Group type: COMPARATOR
Intervention: Nonstress testing
Number of subjects: 1360
Study 11074022 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDLINE search strategies for detecting RCTs in prosthodontics
Number of subjects: 0
Study 11074022 — intervention group
Group type: EXPERIMENTAL
Intervention: Publication type clinical trial
Number of subjects: 0
Study 11074022 — intervention group
Group type: EXPERIMENTAL
Intervention: Publication type randomized controlled trial
Number of subjects: 0
Study 11074022 — intervention group
Group type: COMPARATOR
Intervention: Combining search terms
Number of subjects: 0
Study 8644642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirsidomine 10 mg
Number of subjects: 48
Study 8644642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirsidomine 20 mg
Number of subjects: 48
Study 8644642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirsidomine 40 mg
Number of subjects: 48
Study 8644642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 1467291 — intervention group
Group type: EXPERIMENTAL
Intervention: TL‐01 lamps
Number of subjects: 15
Study 1467291 — intervention group
Group type: COMPARATOR
Intervention: TL‐12 lamps
Number of subjects: 15
Study 29764271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic steroid injection (ITS)
Number of subjects: 47
Study 29764271 — intervention group
Group type: EXPERIMENTAL
Intervention: Canalith repositioning procedure (CRP)
Number of subjects: 47
Study 29764271 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular suppressant (VS)
Number of subjects: 47
Study 27881113 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + EFT (treatment as usual with integrated emotion-focused components)
Number of subjects: 130
Study 27881113 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 130
Study 27881113 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + EFT
Number of subjects: 130
Study 27881113 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 130
Study 25319802 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with manipulation
Number of subjects: 292
Study 25319802 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture without manipulation (sham control)
Number of subjects: 292
Study 23457681 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive pain education (PE) program
Number of subjects: 131
Study 23457681 — intervention group
Group type: COMPARATOR
Intervention: Interactive control program (general dementia education)
Number of subjects: 131
Study 20190370 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 20190370 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0
Study 20190370 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 0
Study 20190370 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronate
Number of subjects: 0
Study 18165461 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem extended release 6.25 mg
Number of subjects: 205
Study 18165461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 16014796 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal pitch stimuli
Number of subjects: 0
Study 16014796 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial width stimuli
Number of subjects: 0
Study 16014796 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of pitch and spatial width
Number of subjects: 0
Study 12970227 — intervention group
Group type: COMPARATOR
Intervention: Inhaled NO (20 ppm)
Number of subjects: 24
Study 12970227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sildenafil (1 mg/kg in 'cath laboratory', 0.25 mg/kg post op)
Number of subjects: 24
Study 10391657 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% of maximal workload on a cycle ergometer (mean load of 32 watts)
Number of subjects: 28
Study 10391657 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% of maximal workload on a cycle ergometer (mean load of 85 watts)
Number of subjects: 28
Study 8675588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 1.0 g/kg
Number of subjects: 13
Study 8675588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.5 g/kg
Number of subjects: 13
Study 8675588 — intervention group
Group type: COMPARATOR
Intervention: Control (no ethanol)
Number of subjects: 13
Study 8675588 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic TRH (1 microgram/kg BW)
Number of subjects: 13
Study 8675588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (any dose)
Number of subjects: 13
Study 1706502 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR pacing (single setting rate responsive)
Number of subjects: 12
Study 1706502 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing (fixed rate demand)
Number of subjects: 12
Study 6517563 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical acyclovir treatment
Number of subjects: 42
Study 6517563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 30508308 — intervention group
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF split tablet (800/150/200/10 mg)
Number of subjects: 30
Study 30508308 — intervention group
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF crushed tablet (800/150/200/10 mg)
Number of subjects: 30
Study 30508308 — intervention group
Group type: COMPARATOR
Intervention: D/C/F/TAF whole tablet (800/150/200/10 mg)
Number of subjects: 30
Study 30089485 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Quality Improvement (CQI) intervention applied at the cluster level with training and mentoring for staff.
Number of subjects: 7
Study 30089485 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving the South African Department of Health standard of care.
Number of subjects: 7
Study 26923235 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week high-intensity interval and resistance training program (EXP group)
Number of subjects: 40
Study 26923235 — intervention group
Group type: COMPARATOR
Intervention: Usual activities of daily living (CTL group)
Number of subjects: 40
Study 24527443 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of alprazolam 0.5 mg and melatonin 3 mg
Number of subjects: 80
Study 24527443 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam 0.5 mg
Number of subjects: 80
Study 24527443 — intervention group
Group type: COMPARATOR
Intervention: Melatonin 3 mg
Number of subjects: 80
Study 24527443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 22880945 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 217
Study 22880945 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplement
Number of subjects: 217
Study 22880945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 22880945 — intervention group
Group type: EXPERIMENTAL
Intervention: Food and micronutrient groups
Number of subjects: 217
Study 22880945 — intervention group
Group type: EXPERIMENTAL
Intervention: Food group
Number of subjects: 217
Study 21172109 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 80
Study 21172109 — intervention group
Group type: COMPARATOR
Intervention: Standard transurethral resection of the prostate (TURP)
Number of subjects: 80
Study 16876559 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (twice a week for 16 weeks)
Number of subjects: 16
Study 16876559 — intervention group
Group type: COMPARATOR
Intervention: Control group (medical therapy only)
Number of subjects: 16